模型引导精准给药对接受持续输注万古霉素成人患者的影响:一项随机对照临床试验
这是一项在比利时两家医院11个病房开展的随机对照试验,纳入接受持续输注万古霉素的住院成人。干预组由临床药师使用CE认证的模型引导精准给药(MIPD)软件计算剂量,目标AUC24h为400至600 mg×h/L;对照组按机构指南接受标准给药与监测。主要终点为开始万古霉素治疗后48至72小时达到目标AUC24h/MIC 400-600的患者比例。
要点
- 干预组由临床药师用CE认证MIPD软件计算剂量,目标AUC24h为400至600 mg×h/L。
- 对照组按机构指南接受标准给药与监测。
- 主要终点为开始治疗后48至72小时达到目标AUC24h/MIC 400-600的患者比例。
核心结论
- 该试验旨在阐明MIPD给药所宣称的获益,并为如何最优监测万古霉素治疗提供新见解。
研究设计与样本
- 随机对照临床试验,受试者来自比利时两家医院11个病房的住院成人,随机分配至干预组或标准治疗对照组。
- 干预组由临床药师使用CE认证的MIPD软件进行剂量计算,目标AUC24h为400至600 mg×h/L。
- 对照组按机构指南接受标准治疗给药与监测。
- 主要终点为开始万古霉素治疗后48至72小时达到目标AUC24h/MIC 400-600的患者比例。
- 次要终点包括治疗期间至停药后48小时内发生(加重)急性肾损伤(AKI)的患者比例、开始治疗后72至96小时达到目标AUC24h/MIC 400-600的患者比例、处于目标AUC24h/MIC 400-600范围内的时间比例。
主要发现
- 原文为试验方案摘要,未报告研究结果。
关键数值与推荐
- 干预组目标AUC24h为400至600 mg×h/L。
- 主要终点目标AUC24h/MIC为400-600,评估时间窗为开始万古霉素治疗后48至72小时。
- 次要终点目标AUC24h/MIC为400-600,评估时间窗为开始万古霉素治疗后72至96小时。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vancomycin is a commonly prescribed antibiotic to treat gram-positive infections. The efficacy of vancomycin is known to be directly related to the pharmacokinetic/pharmacodynamic (PK/PD) index of the area under the concentration-time curve (AUC) divided by the minimal inhibitory concentration (MIC) of the pathogen. However, in most countries, steady-state plasma concentrations are used as a surrogate parameter of target AUC/MIC, but this practice has some drawbacks. Hence, direct AUC-guided monitoring of vancomycin using model-informed precision dosing (MIPD) tools has been proposed for earlier attainment of target concentrations and reducing vancomycin-related nephrotoxicity. However, solid scientific evidence for these benefits in clinical practice is still lacking. This randomized controlled trial (RCT) aims to investigate the clinical utility of MIPD dosing of vancomycin administered via continuous infusion in hospitalized adults. METHODS: Participants from 11 wards at two Belgian hospitals are randomly allocated to the intervention group or the standard-of-care comparator group. In the intervention group, clinical pharmacists perform dose calculations using CE-labeled MIPD software and target an AUC24h of 400 to 600 mg × h/L, whereas patients in the comparator group receive standard-of-care dosing and monitoring according to the institutional guidelines. The primary endpoint is the proportion of patients reaching the target AUC24h/MIC of 400-600 between 48 and 72 h after start of vancomycin treatment. Secondary endpoints are the proportion of patients with (worsening) acute kidney injury (AKI) during and until 48 h after stop of vancomycin treatment, the proportion of patients reaching target AUC24h/MIC of 400-600 between 72 and 96 h after start of vancomycin treatment, and the proportion of time within the target AUC24h/MIC of 400-600. DISCUSSION: This trial will clarify the propagated benefits and provide new insights into how to optimally monitor vancomycin treatment. TRIAL REGISTRATION: EudraCT number: 2021-003670-31. Registered June 28, 2021. CLINICALTRIALS: gov identifier: NCT05535075. Registered September 10, 2022. Protocol version 3, protocol date: April 21, 2023.
引用
- Van Wynsberge G, Grootaert V, Buyle F, et al. Impact of model-informed precision dosing in adults receiving vancomycin via continuous infusion: a randomized, controlled clinical trial. Trials. 2024. PMID: 38365814. doi:10.1186/s13063-024-07965-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。